Follow us on social media
Follow us on social media
Follow us on social media
Follow us on social media
Follow us on social media
Follow us on social networks
Become a BioTechniques member (it’s free!) and get the latest news in the Life Sciences box, member exclusives and 10% on payment processing for BioTechniques items.
Pharmaceutical company CDMO Ardena (Gent, Belgium) announces the expansion of its purification and fractionation capacity at its plant in Södertälje (Sweden) to Novavax (MD, USA). U. S. Department of T in the long-term production of its COVID-19 vaccine.
Following conditional marketing authorization granted by the European Commission, Novavax’s COVID-19 vaccine, called Nuvaxovid, will be the fifth vaccine approved for use in Europe. As a vaccine based on recombinant proteins, the Ardena expansion will meet Novavax’s demand for chromatographic capabilities. Tangential flow filtration and freeze-drying capabilities. Ardena has been a collaborator with Novavax for 15 years for the progression of a fractionation procedure of Matrix-M™, a key adjuvant of Nuvaxovid for the immune reaction against the SARS-CoV-2 virus.
Not a member? Sign up today!
BioTechniques works through Taylor
Impact Factor 1. 993 | CiteScore 2. 0